Evidence map›Paper›PMID 27283497›Full record

ReviewJournal of the American Society of Nephrology : JASN2016

Pragmatic Clinical Trials in CKD: Opportunities and Challenges.

Ian H de Boer, Csaba P Kovesdy, Sankar D Navaneethan, Carmen A Peralta, Delphine S Tuot, Miguel A Vazquez, Deidra C Crews, American Society of Nephrology Chronic Kidney Disease Advisory Group

Abstract readReview
In one paragraph

Review in Journal of the American Society of Nephrology : JASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Trial
  2. Electronic Decision Support for Management of CKD in Primary Care: A Pragmatic Randomized Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2020
    Trial
  3. Trial
  4. Impact of a Primary Care CKD Registry in a US Public Safety-Net Health Care Delivery System: A Pragmatic Randomized Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018
    Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Preparing European Nephrology for the next pandemic: lessons from the ERACODA collaboration.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ian H de BoerDivision of Nephrology and Department of Medicine, Kidney Research Institute, University of Washington, Seattle, WA; deboer@u.washington.edu.
Csaba P KovesdyDivision of Nephrology, University of Tennessee Health Science Center, Memphis, TN; Nephrology Section, Memphis VA Medical center, Memphis, TN.
Sankar D NavaneethanSection of Nephrology, Department of Medicine, Selzman Institute for Kidney Health, Baylor College of Medicine; Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX.
Carmen A PeraltaKidney Health Research Collaborative and Division of Nephrology, University of California San Francisco, San Francisco, CA.
Delphine S TuotDivision of Nephrology, University of California San Francisco, San Francisco, CA.
Miguel A VazquezDivision of Nephrology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.
Deidra C CrewsDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine; and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, MD.
American Society of Nephrology Chronic Kidney Disease Advisory Group

Funding

Improving Chronic Disease Management with Pieces (ICD-Pieces)UH3DK104655 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI VAZQUEZ, MIGUEL A · 2015 to 2019
$5.6M
Kidney Awareness Registry and Education-2R01DK104130 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TUOT, DELPHINE · 2015 to 2019
$2.8M
Lowering Blood Pressure Among Hypertensives with Screen-Detected Kidney DiseaseR34DK102152 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI PERALTA, CARMEN ALICIA · 2014 to 2015
$690k
Health IT Enhanced for CKD in Safety-Net Primary CareR34DK093992 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI POWE, NEIL R. · 2011 to 2013
$686k
Race, Socioeconomic Status, Diet and Chronic Kidney DiseaseK23DK097184 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CREWS, DEIDRA CANDICE · 2013 to 2016
$684k
Pragmatic Randomized Trial of Calcitriol in Patients with Chronic Kidney DiseaseUH2HL125122 · NHLBI · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI DE BOER, IAN H, SCHOLES, DELIA · 2014 to 2014
$563k
NHLBI NIH HHS UH2 HL125122NIDDK NIH HHS K23 DK097184NIDDK NIH HHS R01 DK104130NIDDK NIH HHS R34 DK093992NIDDK NIH HHS R34 DK102152NIDDK NIH HHS UH3 DK104655
6 · The paper itself

Abstract

Randomized controlled trials in CKD lag in number behind those of other chronic diseases, despite the high morbidity and mortality experienced by patients with kidney disease and the exorbitant costs of their health care. Observational studies of CKD frequently yield seemingly paradoxic associations of traditional risk factors with outcomes, making it difficult to extrapolate the results of trials conducted in people with normal kidney function to patients with CKD. However, many completed trials in CKD have been limited by intermediate outcomes of unclear clinical significance or narrow eligibility criteria that limit external validity, and implementation of proven therapies remains a challenge. It is therefore imperative that the nephrology community capitalize on recent interest in novel approaches to trial design, such as pragmatic clinical trials. These trials are meant to promote research within real world settings to yield clinically relevant results with greater applicability than those of traditional trials, while maintaining many advantages, such as controlling for potential sources of bias. We provide a description of pragmatic clinical trials and a discussion of advantages, disadvantages, and practical challenges inherent to this study design, in the context of specific scientific questions relevant to patients with CKD.

Indexed as

Pragmatic Clinical Trials as TopicHumansRenal Insufficiency, Chronicchronic kidney diseaseclinical trialoutcomes

Identifiers

PMID27283497
PMCPMC5042675

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.